AYTU BioPharma, Inc. (AYTU), formerly Aytu BioScience, Inc., is a specialty pharmaceutical company operating from Englewood, Colorado, USA. It primarily focuses on the commercialization of novel products in the therapeutics market. The organization is committed to introducing innovative therapeutic options to improve the health and well-being of patients worldwide. The company plays a substantial role in filling significant treatment gaps in patient care, using its extensive and unique pharmaceutical knowledge and expertise.
Established in 2015, AYTU BioPharma has targeted a diverse range of medical areas such as pediatrics, urology, and respiratory diseases. It has developed and commercialized several innovative products, mainly consisting of diagnostics and therapeutics. AYTU's prominent offerings include the Natesto nasal gel, intended for testosterone replacement therapy; ZolpiMist, an oral spray for insomnia; and Tuzistra XR for cough and respiratory ailments.
Additionally, AYTU BioPharma utilizes its distribution platform to commercialize a broad range of novel diagnostic tests. It entered the spotlight with its quick distribution of COVID-19 IgG/IgM rapid tests amid the global pandemic which reinforced its commitment to public health needs.
AYTU BioPharma's growth strategy is underpinned by a focus on novel product acquisitions, internal product development, and robust market launches. They are constantly exploring opportunities to expand their portfolio by seeking products and technologies that address significant patient needs in large and growing markets.
More recently, the company has made its foray into the rapidly evolving field of psychedelic medicine by acquiring the rights to the novel drug candidate NLS-1, a formulation of the psychedelic compound DMT.
AYTU BioPharma, Inc is publicly traded on NASDAQ under its ticker symbol 'AYTU'. It operates as a relatively small player in the vast pharmaceutical industry but continues to show its value by developing and bringing to market a range of innovative healthcare solutions. With a bustling pipeline and a proactive approach to addressing unmet medical needs, AYTU BioPharma is well geared to establish its presence and make significant strides in the global pharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Aytu BioPharma, Inc. (Nasdaq:AYTU) is set to announce its fiscal 2027 first-quarter operational and financial results after the market closes on Monday, November 16, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss the results, followed by a Q&A session. A teleconference replay will be available until November 30, 2026.
The FDA has approved a labeling supplement (SUPPL-13) for ZOLPIMIST, a discontinued zolpidem spray manufactured by Aytu BioPharma Inc. The approval, issued on November 9, 2026, pertains only to the package insert and does not indicate a new indication or current sales change for the product, which is listed as discontinued. This update is considered negative for shareholders as ZOLPIMIST is no longer marketed.
This article compares Elite Pharmaceuticals (ELTP) and Aytu BioPharma (AYTU), two pharmaceutical companies focused on CNS treatments, including ADHD. While both appear undervalued compared to the sector, Elite Pharmaceuticals is recommended as the better buy due to its established generic portfolio, expanding pipeline, financial stability, and lower execution risk, offering a more balanced risk-reward profile than Aytu, whose growth relies heavily on the new EXXUA launch.
Aytu BioPharma informó un aumento del 6% interanual en los ingresos netos del cuarto trimestre fiscal de 2026, alcanzando los 16,1 millones de dólares, impulsado por el fuerte crecimiento de EXXUA y el sólido rendimiento de su negocio de TDAH. La compañía logró un EBITDA ajustado positivo de 0,5 millones de dólares y redujo su pérdida neta a 0,1 millones de dólares, manteniendo una posición de efectivo estable en 26,3 millones de dólares. Para el año fiscal 2027, Aytu BioPharma proyecta gastos operativos en efectivo de entre 45 y 49 millones de dólares y espera un EBITDA ajustado positivo en la segunda mitad del año.